ACOG Key Statistics, Chart & Performance
The current stock price of ACOG is 5.81 USD. In the past month the price increased by 0.17%. In the past year, price increased by 2.65%.
ACOG Latest News, Press Relases and Analysis
ACOG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.36 | 406.92B | ||
| AMGN | AMGEN INC | 15.79 | 186.00B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.68 | 117.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.08 | 76.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 928.02 | 62.53B | ||
| INSM | INSMED INC | N/A | 44.10B | ||
| NTRA | NATERA INC | N/A | 32.88B | ||
| BIIB | BIOGEN INC | 10.8 | 26.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.23 | 20.71B | ||
| INCY | INCYTE CORP | 15.81 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About ACOG
Company Profile
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 52 full-time employees. The company went IPO on 2021-06-09. The firm's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Company Info
ALPHA COGNITION INC
c/o 1200 - 750 West Pender Street
Vancouver BRITISH COLUMBIA CA
Employees: 52
Phone: 16045649244
ALPHA COGNITION INC / ACOG FAQ
Can you describe the business of ALPHA COGNITION INC?
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 52 full-time employees. The company went IPO on 2021-06-09. The firm's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
What is the current price of ACOG stock?
The current stock price of ACOG is 5.81 USD. The price increased by 1.57% in the last trading session.
What is the dividend status of ALPHA COGNITION INC?
ACOG does not pay a dividend.
How is the ChartMill rating for ALPHA COGNITION INC?
ACOG has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does ALPHA COGNITION INC belong to?
ALPHA COGNITION INC (ACOG) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of ALPHA COGNITION INC (ACOG) based on its PE ratio?
ALPHA COGNITION INC (ACOG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.3).
What is ALPHA COGNITION INC worth?
ALPHA COGNITION INC (ACOG) has a market capitalization of 126.31M USD. This makes ACOG a Micro Cap stock.
ACOG Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ACOG. When comparing the yearly performance of all stocks, ACOG is a bad performer in the overall market: 81.84% of all stocks are doing better.
ACOG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACOG. ACOG has a great financial health rating, but its profitability evaluates not so good.
ACOG Financial Highlights
Over the last trailing twelve months ACOG reported a non-GAAP Earnings per Share(EPS) of -1.3. The EPS increased by 38.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.35% | ||
| ROE | -62.75% | ||
| Debt/Equity | 0 |
ACOG Forecast & Estimates
7 analysts have analysed ACOG and the average price target is 18.36 USD. This implies a price increase of 216.01% is expected in the next year compared to the current price of 5.81.